Posts Tagged Pharmaceutical Market Europe
The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »
You won’t generally find PME issues following a particular theme each month – there’s simply too much interesting ground to cover in the magazine for that.
Nevertheless, as each issue coalesces there are often common strands across different features and such seemed the case with March’s PME, which contains a nice chunk of ‘careers’ content. Read the rest of this entry »
In this month’s issue of PME magazine we balance the changes that are already the theme of 2017 with some much needed stability in the form of a look at family-owned or foundation-run pharmaceutical companies.
Such European businesses include Germany’s Boehringer Ingelheim, Italy’s Chiesi and Denmark’s LEO Pharma, whose president and CEO Gitte Aabo talked to us about playing the long game and how this sees it through times of boom and bust. Read the rest of this entry »
This month in PME we hear from the European Commissioner for Health on the burden European countries face from chronic diseases.
Dr Vytenis Andriukaitis tells of his concern about the growth in conditions such as cardiovascular diseases, cancer and type 2 diabetes, and how EU Member States need to be supported if they are to be tackled. Read the rest of this entry »
For this month’s issue of PME I spoke with Ipsen’s new chief executive David Meek about his company’s strategy for growth and – appropriately enough, as we sat down at the ESMO meeting in Copenhagen – his hopes for Ipsen’s new cancer drug Cabometyx.
We covered the strategic pillars Ipsen is counting on for success and looked at the strong progress the French firm is making in the US – where for the first year its operations there are its number one affiliate by revenue – and the changes to its primary care business model in China. Read the rest of this entry »
There’s no shortage of ambition at GlaxoSmithKline, whose chief immunology officer and senior vice president of their R&D pipeline Paul-Peter Tak we spoke to for this month’s executive interview.
Having joined the company five years ago from an academic medical centre in Amsterdam, he says he was driven to move to the industry because he wanted to have a bigger impact on patients’ lives. Read the rest of this entry »
How confident are you in your country’s healthcare system? That was the central issue for this month’s PME cover feature, which focused on a global study of healthcare perceptions and offered some useful insights into how people think and feel when faced with healthcare decisions.
We also looked at the global scourge that is the problem of counterfeit medicines and hear what the industry is doing to help tackle the problem. Read the rest of this entry »